# Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)

> **NCT06030193** · PHASE2 · COMPLETED · sponsor: **Qlaris Bio, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Normal Tension Glaucoma (NTG)
- Low-Tension Glaucoma, Bilateral
- Low-Tension Glaucoma, Unspecified Eye
- Glaucoma

## Interventions

- **DRUG:** QLS-111 ophthalmic solution (0.015%)
- **DRUG:** Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)

## Key facts

- **NCT ID:** NCT06030193
- **Lead sponsor:** Qlaris Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-13
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-03-23
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030193, "Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06030193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*